<img src="https://ml.globenewswire.com/Resource/Download/ce96f659-56dd-4218-a734-62efad33d7db?size=2" nborder="0" align="left" hspace="5" vspace="5" title="NEWEST DSS_logo1.png" alt="DSS, Inc."/>ROCHESTER, N.Y., Sept. 16, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties. DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar. “We are pleased to see Impact reach this important milestone in its proposed Business Combination with Zoar,” said Jason Grady, Chief Executive Officer of DSS, Inc. “The filing of the Form F-4 demonstrates continued momentum toward the proposed transaction and represents another step in the evolution of Impact. We believe the combination has the potential to strengthen Impact’s platform, expand its opportunities for future growth, and ultimately create meaningful value for DSS and our shareholders.” The Registration Statement includes a preliminary proxy statement of Impact and a prospectus of Zoar relating to the proposed transaction. The filing remains subject to SEC review and has not yet been declared effective. The proposed Business Combination remains subject to a number of conditions, including the Registration Statement being declared effective by the SEC, approval of the transaction by Impact stockholders, approval of the listing of Zoar ordinary shares on NYSE American, and the satisfaction or waiver of other conditions contained in the applicable merger and share exchange agreement. The filing of the Registration Statement does not mean that the Registration Statement has been declared effective, that the SEC has completed its review, that Impact stockholders have approved the proposed transaction, or that the transaction will be completed. About DSS, Inc. DSS, Inc. (NYSE American: DSS) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit <a href="https://www.globenewswire.com/Tracker?data=1xq84Y-axi3zuwxqmYA73Qfn5fmVvdflCwQ3J6gGvjSmCNSAHR1smeA1SJsKOOsEd2RKjKY3H-qm_O_PW9c5iFay3KEhYcWzd9R_RjxX25Q=" rel="nofollow" target="_blank" title="www.dssworld.com">www.dssworld.com</a>. Additional Information and Where to Find It In connection with the proposed Business Combination, Zoar Limited has filed with the SEC a Registration Statement, which includes a preliminary proxy statement of Impact that also constitutes a prospectus of Zoar. Investors and security holders are urged to read the Registration Statement, the proxy statement/prospectus and any other relevant documents filed or to be filed with the SEC, as well as any amendments or supplements to those documents, carefully and in their entirety when they become available because they contain or will contain important information regarding the proposed transaction. Copies of these documents may be obtained without charge through the SEC’s website. No Offer or Solicitation This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor does it constitute a solicitation of any vote, proxy, consent or approval in connection with the proposed transaction. No offer or sale of securities shall be made except in accordance with applicable securities laws. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, among others, statements concerning the proposed Business Combination, the anticipated completion of the transaction, the effectiveness of the Registration Statement, stockholder and regulatory approvals, the proposed listing of Zoar ordinary shares and the anticipated ownership of PubCo following the transaction. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. DSS undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations DSS, Inc. <a href="https://www.globenewswire.com/Tracker?data=0kpYrmm0Z5tm1DMvXqWEDcRDiSG9w7zWhrZ-vb_GlppvPnFm4TG-vetE9u6Xawf_Z9nCXpylFQ_ijLEQ3mBX-11JMHvrdmHfGd0aph01Tnk=" rel="nofollow" target="_blank" title="ir@dssworld.com">ir@dssworld.com</a> +1 (585) 565-2422 <img alt="" src='https://ml.globenewswire.com/media/NDEwZjQyNjEtMzJlNi00OWFjLWFkMTktMjdmOTE3YWFlZTFmLTExMDUzMDItMjAyNi0wOS0xNi1lbg==/tiny/DSS-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn